Rongrong Zheng
机构：Hangzhou Xixi hospital · ORCID：0009-0001-0052-5128
发表论文 92 篇 · 总被引 2573 次 · h-index 26
代表论文
- Chemotherapy‐Enabled Colorectal Cancer Immunotherapy of Self‐Delivery Nano‐PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance (2024 · Advanced Science · 被引 65)
- Carrier-Free Nano-PROTACs to Amplify Photodynamic Therapy Induced DNA Damage through BRD4 Degradation (2023 · Nano Letters · 被引 65)
- Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05) (2024 · Journal of Clinical Oncology · 被引 50)
- First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study (2024 · Signal Transduction and Targeted Therapy · 被引 43)
- Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial (2024 · Clinical and Translational Medicine · 被引 20)
- Multi‐synergistic chemotherapeutic drug assemblies to activate colorectal cancer immunotherapy by modulating the multilevel immunosuppressive characteristics (2024 · Aggregate · 被引 13)